Samra Turajlic is a a Consultant Medical Oncologist at the Royal Marsden sub-specialising in the treatment of melanoma and kidney cancer. She completed her undergraduate medical studies at Oxford University and clinical training at UCL completing specialist training in medical oncology. Samra gained a PhD in 2013 from the Institute of Cancer Research in the field of melanoma genetics and targeted therapy resistance.  She became an independent Group Leader at the Francis Crick Institute in 2019 and divides her time between the clinic and her lab. Her goal is to develop an evolutionary understanding of cancer through interdisciplinary research for patient benefit, including therapy and methods development.